Loading...

GLUE MONTE ROSA THERAPEUTICS INC US FDA Inspections 8-K Filing

MNT

GL

MONTE ROSA THERAPEUTICS INC

(GLUE)

2024 8-K

Summary

Summary

Collaboration Agreement

Financial Statements

Financial Statements

Financial Results

Financial Update

Director Appointment

Clinical Trial Update

License Agreement

Financial Results Announcement

Annual Meeting of Stockholders

Promotion of Jennifer Champoux

Underwriting Agreement for ...

Earnings Reports

Resignation of Chief Scient...

Financial Results and Corpo...

Corporate Update and Key Mi...

Financial Results Announcement

Securities Purchase Agreement

Collaboration and License A...

Financial Results Announcement

Appointment of Director

Amendment Approval at Annua...

Financial Results Announcement

Appointment of Director

Financial Results and Corpo...

Corporate Update and Antici...

External Links:

Monte Rosa Therapeutics provided an update on its MRT-2359 Phase 1/2 study for treating MYC-driven solid tumors, reporting favorable safety profiles at specific doses and plans to share more data in Q1 2025.

AI Assistant

MONTE ROSA THERAPEUTICS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.